Bausch & Lomb (BLCO) director Karen Ling awarded 15,842 RSUs as annual equity grant

Rhea-AI Filing Summary

Ling Karen reported acquisition or exercise transactions in this Form 4 filing.

Bausch & Lomb Corp director Karen Ling received an equity grant rather than buying shares on the market. She was awarded 15,842 common shares at a reference price of $15.78 per share as part of her annual restricted share unit (RSU) grant for non-employee directors. Following this award, she directly holds 61,518 common shares. The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders, when they will be settled in common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ling Karen

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Shares, No Par Value	15,842	$15.78	$250K

Holdings After Transaction: Common Shares, No Par Value — 61,518 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 15,842 shares Grant value per share: $15.78 per share Total shares after grant: 61,518 shares

3 metrics

RSUs granted 15,842 shares Annual non-employee director grant

Grant value per share $15.78 per share Reference price for RSU award

Total shares after grant 61,518 shares Direct holdings following transaction

Key Terms

restricted share units ("RSUs"), 2022 Omnibus Incentive Plan, annual meeting of shareholders

3 terms

restricted share units ("RSUs") financial

"Reflects the annual grant of restricted share units ("RSUs") to non-employee directors"

2022 Omnibus Incentive Plan financial

"under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated"

annual meeting of shareholders financial

"The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ling Karen

(Last) (First) (Middle)

C/O BAUSCH + LOMB CORPORATION

520 APPLEWOOD CRESCENT

(Street)

VAUGHAN L4K 4B4

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bausch & Lomb Corp [ BLCO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares, No Par Value	05/26/2026		A		15,842(1)	A	$15.78	61,518	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the annual grant of restricted share units ("RSUs") to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated. Vested RSUs are settled in common shares, no par value, of Bausch + Lomb Corporation. The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

	/s/ Debra E. Levin, attorney-in-fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bausch & Lomb (BLCO) director Karen Ling report in this Form 4?

Karen Ling reported an equity award, not a market purchase or sale. She received 15,842 restricted share units that will settle in common shares, reflecting her annual compensation as a non-employee director under the company’s 2022 Omnibus Incentive Plan.

How many Bausch & Lomb (BLCO) shares did Karen Ling acquire in this transaction?

She acquired 15,842 common shares through a grant of restricted share units. These RSUs represent her annual non-employee director award and will convert into common shares upon vesting, rather than being bought in the open market at the grant date.

What is Karen Ling’s total Bausch & Lomb (BLCO) shareholding after this Form 4?

After this award, Karen Ling directly holds 61,518 common shares. This total reflects the new 15,842-share grant added to her prior holdings, as reported in the Form 4, and represents her current direct ownership position in the company.

At what price were Karen Ling’s Bausch & Lomb (BLCO) RSUs valued in the grant?

The 15,842 restricted share units were granted at a reference value of $15.78 per share. This price is used for reporting and compensation purposes and does not represent an open-market purchase or sale by the director on the grant date.

When do Karen Ling’s Bausch & Lomb (BLCO) RSUs from this grant vest?

The RSUs are scheduled to vest immediately before the conclusion of the next annual meeting of shareholders. Once vested, the restricted share units will be settled in Bausch & Lomb common shares, increasing her directly held share count at that time.

Is Karen Ling’s Bausch & Lomb (BLCO) Form 4 transaction a routine compensation grant?

Yes. The filing describes this as the annual grant of restricted share units to a non-employee director under Bausch & Lomb’s 2022 Omnibus Incentive Plan, as amended and restated, indicating it is a regular element of director compensation rather than a discretionary share trade.